Evidence map›Paper›PMID 37936381›Full record

ReviewTherapeutic advances in respiratory disease

Stepwise management of COPD: What is next after bronchodilation?

Marc Miravitlles, Kazuto Matsunaga, Michael Dreher

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 3 countries.

Marc MiravitllesPneumology Department, University Hospital Vall d'Hebron/Vall d'Hebron Research Institute (VHIR, Vall d'Hebron Barcelona Hospital Campus; CIBER de Enfermedades Respiratorias [CIBERES]), P. Vall d'Hebron 119-129, Barcelona 08035, Spain.ORCID 0000-0002-9850-9520
Kazuto MatsunagaDepartment of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan.
Michael DreherDepartment of Pneumology and Intensive Care Medicine, University Hospital Aachen, Aachen, Germany.ORCID 0000-0002-3452-5329
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESUniversitätsklinikum Aachen · DEYamaguchi University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhaled bronchodilator therapy with long-acting muscarinic antagonists (LAMAs) and long-acting β

Indexed as

AsthmaEosinophiliaPulmonary Disease, Chronic ObstructiveAdministration, InhalationAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsDrug Therapy, CombinationHumansMuscarinic AntagonistsAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsMuscarinic AntagonistsCOPDdyspnoeaeosinophilsexacerbationsinhaled corticosteroidslong-acting beta-agonists

Identifiers

PMID37936381
PMCPMC10631322
OpenAlexW4388500593

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.